Alzheimer’s Drug Discovery Foundation (ADDF): Translational and Clinical Research on Alzheimer’s Disease

(Proposal due 16.6, LOI due 2 weeks prior)
ADDF is interested in novel targets and therapeutic approaches for Alzheimer’s Disease (AD), related dementias and cognitive aging. ADDF funds drug discovery and preclinical development, early detection, clinical trials and prevention, but NOT basic research. These areas include, but are not limited to: Energy utilization/mitochondria function, insulin sensitivity, protein degradation/autophagy, ApoE function and cholesterol metabolism, vesicular trafficking, inflammatory pathways, synaptic function/morphology, calcium regulation, myelin changes, ischemia and oxidative stress, vascular injury, the blood-brain barrier interface, and translatable biomarkers. ADDF has limited interest in funding anti-amyloid approaches and has limited interest in funding cholinesterase inhibitor programs. Funding priorities: Early identification; Prevention of AD and cognitive decline; Treatment of AD and cognitive aging.

* Preclinical Drug Discovery: Drug discovery and biomarker development.. Funding averages $150K/year. In some cases, multi-year proposals can be considered.
* Program to Accelerate Clinical Trials: Funding- up to $1.5M per application, is offered to increase the number of innovative drugs tested in humans.
* ADDF/NIH: financial assistance for relevant NIA and NINDS grant applications that were scored but not funded AND fall within the ADDF’s current funding priorities (Application deadline is rolling)
http://www.alzdiscovery.org/research-and-grants/request-for-proposal